Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
ABI-009 (
nab
-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
Home
ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
Next Post
Previous Post
ABI-009 (
nab
-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
UPDATE — Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
Institutional experience with
nab
-sirolimus in patients with malignancies harboring
TSC1
or
TSC2
mutations
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Phase II Trial of
nab
-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update
Read More
Andrew Kwon, PhD
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.